Private: Gallery Post #1

19

Apr2021

Breaking News: 2 Reporting Periods for PMPRB MLP Compliance for Grandfathered and Gap Medicines

The PMPRB has announced it has revisited it’s March 17, 2021 decision regarding timelines for compliance for Grandfathered and Gap medicines.  The Board has reset the maximum list price (MLP) compliance timeline for these drugs to 2 PMPRB reporting periods, rather than their amended 1 reporting period timeline. MLP compliance for ... Read More

14

Apr2021

NACI Process For Incorporating Economic Evidence Into Federal Vaccine Recommendations Consultation

BACKGROUNDThe National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.Traditionally, NACI reviewed safety, efficacy, immunogenicity, effectiveness and burden of illness in making recommendations for vaccine programs. PHAC has now expanded ... Read More

29

Mar2021

CADTH Releases Pharmaceuticals Reviews Update – Issue 22

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CADTH reimbursement review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.... Read More

29

Mar2021

Patented Medicine Prices Review Board (PMPRB) 2019 Annual Report Published

The PMPRB has published the long awaited 2019 Annual Report. The following are some of the high-level takeaways: Sales of patented medicines in Canada reached $17.2 billion in 2019, a moderate increase of 3.5% from the ... Read More

24

Mar2021

REMINDER: PDCI Sharing Sites for Policy Submissions Open for Contribution!

This is a reminder that PDCI is inviting all stakeholders to share their input for public awareness and information. PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals to share their submissions here so ideas ... Read More

18

Mar2021

PMPRB February 15th Consultation – Decision made for Gap Medicines and Timelines for Compliance

On January 15, 2021, PMPRB invited stakeholders to comment on two key amendments to the final guidelines that were originally to come into affect for January 1, 2021 but were delayed to July 1, 2021. PMPRB received 48 submissions in response to the definition of Gap Medicines and ... Read More

12

Mar2021

PDCI Launches Two New Sharing Sites for Policy Submissions: 1. Federal ISED Biomanufacturing Consultation 2. Health Canada National Drugs for Rare Diseases Consultation

Biomanufacturing Consultations - Consultations Open Until March 12 Earlier this year, the Government of Canada invited submissions on the topic of considering the creation of new biomanufacturing capacity for Canadians. Innovation, Science and Economic Development Canada (ISED), in partnership ... Read More

26

Feb2021

Welcome Chris Boodoo and Hussein El-Khechen to the PDCI Team!

PDCI Market Access has further expanded its HTA Team! Chris joins PDCI as a Senior Health Economist. Chris holds a MSc. in Health Services Research from the University of ... Read More

19

Feb2021

PDCI Launches Sharing Page for Submissions to the PMPRB Proposed Amendments to the New Guidelines

On December 29, 2020, the coming into force date for the amended PMPRB regulations and guidelines were further delayed to July 1, 2021.  The PMPRB has invited stakeholders to comment on two critical amendments to the regulations with responses due by February 15th. Specifically, the PMPRB proposes ... Read More

15

Jan2021

PMPRB Proposes Amendments to New Guidelines: Requests Consultation from Stakeholders

On January 13th 2021, as a consequence of the new PMPRB coming-into-force date, PMPRB has invited stakeholders to comment on two proposed amendments to the New Guidelines.  The two amendments pertain to (A) the Definition of Gap Medicines and (B) Compliance Timelines with Maximum List ... Read More